# Usefulness of DORNASE in COVID-19 on HFNO

> **NCT05139901** · PHASE4 · TERMINATED · sponsor: **University Medical Centre Ljubljana** · enrollment: 10 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Dornase Alfa
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT05139901
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to the Omicron version of SARS-CoV-2 the COVID-pneumonia patients ran out
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139901, "Usefulness of DORNASE in COVID-19 on HFNO". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05139901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*